To hear about similar clinical trials, please enter your email below
Trial Title:
Plasma Exosome RNA to Diagnose Prostate Cancer
NCT ID:
NCT06604130
Condition:
Prostate Cancer
Conditions: Official terms:
Prostatic Neoplasms
Conditions: Keywords:
Prostate cancer
RNA
Diagnosis
Combination
Study type:
Interventional
Study phase:
N/A
Overall status:
Enrolling by invitation
Study design:
Allocation:
N/A
Intervention model:
Sequential Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Prostate cancer screening decision
Description:
The subjects would receive serum PSA test.
Arm group label:
The experimental arm receiving diagnosis from serum RNA combination
Summary:
The aim of the present study is to investigate a RNA combination to diagnose prostate
cancer.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Blood prostate-specific antigen PSA>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital
rectal examination, ultrasound examination, magnetic resonance imaging, and PSMA
PET/CT examination.
3. The patient is willing to undergo prostate biopsy.
Exclusion Criteria:
1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician's judgment, serious complications may occur
and affect the normal conduct of the experiment
Gender:
Male
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Xijing Hospital
Address:
City:
Xian
Zip:
710032
Country:
China
Start date:
March 12, 2021
Completion date:
July 31, 2025
Lead sponsor:
Agency:
Xijing Hospital
Agency class:
Other
Source:
Xijing Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06604130
